U.S. Markets open in 6 hrs 11 mins

Anthera Pharmaceuticals, Inc. (ANTH)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.35-0.02 (-1.46%)
At close: 4:00PM EDT
People also watch
AVEOAPRIFOLDALIMCLSN

Anthera Pharmaceuticals, Inc.

25801 Industrial Boulevard
Suite B
Hayward, CA 94545
United States
510-856-5600
http://www.anthera.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees33

Key Executives

NameTitlePayExercisedAge
Mr. Paul F. Truex MBAExec. Chairman626.32k4.36k48
Mr. John Craig ThompsonChief Exec. Officer, Pres and Director533.55kN/A50
Ms. May LiuChief Accounting Officer, Sr. VP of Fin. & Admin. and Compliance Officer373.44kN/A41
Dr. William R. Shanahan Jr., M.D., J.D.Chief Medical Officer and Sr. VP195.95kN/A68
Ms. Klara A. Dickinson-EasonAdvisor417.89kN/A49
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, CA, US.

Corporate Governance

Anthera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.